Huadong Medicine Co., Ltd
Huadong Medicine Co., Ltd., a prominent player in the pharmaceutical industry, is headquartered in China (CN) and operates extensively across various regions. Founded in 1993, the company has established itself as a leader in the development, manufacturing, and distribution of high-quality pharmaceutical products. Specialising in innovative medicines, Huadong Medicine focuses on areas such as oncology, cardiovascular health, and central nervous system disorders. Their commitment to research and development has led to the creation of unique formulations that address unmet medical needs, setting them apart in a competitive market. With a strong market position, Huadong Medicine has achieved significant milestones, including numerous product approvals and partnerships that enhance its global reach. The company’s dedication to quality and innovation continues to drive its success in the ever-evolving healthcare landscape.
DitchCarbon Score
How does Huadong Medicine Co., Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Huadong Medicine Co., Ltd's score of 26 is lower than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Huadong Medicine Co., Ltd's reported carbon emissions
In 2023, Huadong Medicine Co., Ltd reported total Scope 1 emissions of approximately 14,288,850 kg CO2e. The combined total for Scope 1 and Scope 2 emissions reached about 152,103,450 kg CO2e. This marks an increase from 2022, where Scope 1 emissions were about 11,305,600 kg CO2e, and the total for Scope 1 and Scope 2 was approximately 108,596,090 kg CO2e. Despite these figures, Huadong Medicine has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The company does not currently report on Scope 2 or Scope 3 emissions, which limits the comprehensiveness of their climate impact assessment. Furthermore, there are no climate pledges or commitments to industry-standard initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP) that have been reported. As a significant player in the pharmaceutical industry, Huadong Medicine's emissions data reflects the broader challenges faced by the sector in addressing climate change. The absence of reduction targets suggests an opportunity for the company to enhance its sustainability strategy and align with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 11,305,600 | 00,000,000 |
| Scope 2 | - | - |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Huadong Medicine Co., Ltd is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
